HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.

Abstract
Resistance to FLT3 inhibitors is a serious clinical issue in treating acute myelogenous leukemia (AML). AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance. It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance mutations, and thereby prolong clinical responses. To test this hypothesis, we attempted to isolate AML cell clones resistant to AMG 925 or to FLT3 inhibitors. After a selection of over 8 months with AMG 925, we could only isolate partially resistant clones. No new mutations in FLT3 were found, but a 2- to 3-fold increase in total FLT3 protein was detected and believed to contribute to the partial resistance. In contrast, selection with the FLT3 inhibitors sorafenib or AC220 (Quizartinib), led to a resistance and the appearance of a number of mutations in FLT3 kinase domains, including the known hot spot sites D835 and F691. However, when AC220 was combined with the CDK4 inhibitor PD0332991 (palbociclib) at 0.1 μmol/L or higher, no resistance mutations were obtained, indicating that the CDK4-inhibiting activity of AMG 925 contributed to the failure to develop drug resistance. AMG 925 was shown to potently inhibit the FLT3 inhibitor-resistant mutation D835Y/V. This feature of AMG 925 was also considered to contribute to the lack of resistance mutations to the compound. Together, our data suggest that AMG 925 has the potential to reduce resistance mutations in FLT3 and may prolong clinical responses.
AuthorsCong Li, Liqin Liu, Lingming Liang, Zhen Xia, Zhihong Li, Xianghong Wang, Lawrence R McGee, Katie Newhall, Angus Sinclair, Alexander Kamb, Dineli Wickramasinghe, Kang Dai
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 14 Issue 2 Pg. 375-83 (Feb 2015) ISSN: 1538-8514 [Electronic] United States
PMID25487917 (Publication Type: Journal Article)
Copyright©2014 American Association for Cancer Research.
Chemical References
  • 2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone
  • Benzothiazoles
  • Heterocyclic Compounds, 3-Ring
  • Naphthyridines
  • Phenylurea Compounds
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridines
  • quizartinib
  • fms-Like Tyrosine Kinase 3
  • Cyclin-Dependent Kinase 4
  • palbociclib
Topics
  • Apoptosis (drug effects)
  • Benzothiazoles (pharmacology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cell Separation
  • Clone Cells
  • Cyclin-Dependent Kinase 4 (antagonists & inhibitors, metabolism)
  • Drug Resistance, Neoplasm (drug effects)
  • Heterocyclic Compounds, 3-Ring (pharmacology)
  • Humans
  • Leukemia, Myeloid, Acute (pathology)
  • Mutation (genetics)
  • Naphthyridines (pharmacology)
  • Phenylurea Compounds (pharmacology)
  • Piperazines (pharmacology)
  • Protein Kinase Inhibitors (pharmacology)
  • Pyridines (pharmacology)
  • Signal Transduction (drug effects)
  • fms-Like Tyrosine Kinase 3 (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: